Home
contact us  /  email
about us
portfolio
team
news
Nov 06, 2014
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
Globe Newswire
Coherus BioSciences, Inc. (Nasdaq:CHRS) announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share   more >>
Jul 29, 2014
Proteus Digital Health™ Continues to Build Momentum, Most Recent Round of Funding Reaches over $172MM
Proteus Digital Health, Inc., Redwood City, California
Proteus Digital Health, Inc., the leading digital medicines company, today announced that it has completed a second closing of its Series G financing, raising over $172 million and adding additional respected institutional investors.   more >>
Mar 04, 2014
Invuity® Raises $36 Million in Series E Financing
Invuity, Inc., San Francisco, California
Invuity, Inc., a developer of advanced medical devices to dramatically improve access and visualization in minimally invasive and minimal access surgeries, announced today that it has secured $36 million in a Series E financing led by HealthCare Royalty Partners (“HC Royalty”), along with existing investors Valence Life Sciences, InterWest Partners, Kleiner Perkins Caufield and Byers, and a number of other qualified investors.   more >>
Sep 03, 2013
Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars
Baxter International, Deerfield, Illinois, and Coherus Biosciences, Redwood City, California
Baxter International Inc. (NYSE:BAX) and Coherus Biosciences, Inc. today announced that they have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept   more >>
Jul 26, 2013
Soldiers, Athletes Watched from Inside by Tiny Pill
Bloomberg, USA
Bloomberg TV takes a look at the emerging market of ingestible electronics, including technologies developed by Proteus Digital Health   more >>
Apr 18, 2013
Novation to Offer Invuity® Products to 65,000 Member Hospitals and Affiliates
Invuity, Inc., San Francisco, California
Group Purchasing Agreement Optimizes Invuity’s Sales Force to Support Rapid Multi-Specialty Adoption of EigrTM Illumination Technology   more >>
Apr 11, 2013
NASDAQ Welcomes Chimerix, Inc. to The NASDAQ Stock Market
The NASDAQ OMX Group, Inc.
The NASDAQ OMX Group, Inc. announces an IPO of Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need.   more >>
Jul 05, 2012
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
Proteus Digital Health, Redwood City, California and Otsuka Pharmaceutical Co., Tokyo, Japan
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.   more >>
May 10, 2012
Coherus Biosciences and Daiichi Sankyo Establish Strategic Collaboration to Develop and Commercialize Biosimilar Candidates
Coherus Biosciences, Redwood City, USA
Coherus BioSciences, Inc. and Daiichi Sankyo, Co. Ltd. announced the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan   more >>
News archive >>

 
 
© Helix Ventures 2008 – 2015   /   about us   /   portfolio   /   team   /   news   /   contact us